Publicacions en col·laboració amb investigadors/es de Hospital Universitario de la Princesa (47)

2024

  1. COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant

    Cancers, Vol. 16, Núm. 2

  2. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  3. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  2. LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

    Frontiers in Immunology, Vol. 14

2022

  1. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

2019

  1. Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study

    British Journal of Haematology

2017

  1. IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients

    Journal of Medical Virology, Vol. 89, Núm. 4, pp. 685-695

  2. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients

    Bone Marrow Transplantation

  3. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2016

  1. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2015

  1. Cytomegalovirus infection management in allogeneic stem cell transplant recipients: A national survey in Spain

    Journal of Clinical Microbiology, Vol. 53, Núm. 8, pp. 2741-2744

  2. Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia

    Journal of Medical Virology, Vol. 87, Núm. 9, pp. 1601-1607

  3. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+ T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation

    Transplant Infectious Disease, Vol. 17, Núm. 3, pp. 361-370

2014

  1. An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation

    Journal of Medical Virology, Vol. 86, Núm. 5, pp. 806-811

  2. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study

    British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674

  3. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients

    Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307

2013

  1. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: A Spanish survey

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 477-483

2012

  1. Functional profile of cytomegalovirus (CMV)-specific CD8 + T cells and kinetics of NKG2C + NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients

    Journal of Medical Virology, Vol. 84, Núm. 2, pp. 259-267